Drugs / rAd.CD40L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02719015 | Mar 2018 → Mar 2022 | melanoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAd.CD40L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02719015 ↗ |
| Route | Other | “as an injection directly into 1-3 tumors every 3 weeks” NCT02719015 ↗ |